Saturday 17 October 2026
Export KTTA’s income statement to Excel — free account
Pasithea Therapeutics Corp.
KTTA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 75.8% and free cash flow fell 21.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.42
0.01
+2.44%
Follow KTTA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (65.49%) | (58.22%) | (58.36%) | (89.90%) |
+8 more TTM periods Free account |
|
| (61.97%) | (55.58%) | (53.54%) | (83.64%) | ||
ROIC |
(367.46%) | (319.73%) | 0.00% | (108.52%) | |
Return on Tangible Assets |
(45.88%) | (38.51%) | (39.68%) | (325.00%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.55) | (0.70) | (2.14) | (1.65) | |
Free Cash Flow |
(17.78) | (16.94) | (15.07) | (12.26) | |
Capital Expenditures |
— | — | 0.14 | — | |
| Other line items | |||||
Cash ROIC |
(18.60%) | (16.09%) | (13.64%) | (74.60%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.84 | 0.86 | 0.74 | 0.91 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.21 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.55) | (0.70) | (2.16) | (1.65) | |
Capex per Share |
0.00 | 0.00 | 0.02 | 0.00 | |
Capex to Sales |
— | — | 0.00 | — |
Columns are period end dates